FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only nilotinib formulation that…
Company News
MSD secures worldwide license for LaNova’s LM-299
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy
Valo Health appoints Brian Alexander as CEO
BioNTech signs agreement to acquire Biotheus
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
